Research Capital analyst Andre Uddin has maintained a “Speculative Buy” rating and C$3.50 target on Spectral Medical ...

By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...

Go behind the scenes with Jim Cramer and Jeff Marks of the CNBC Investing Club as they talk candidly about the market's ...

Q4 2025. Management View. CEO Harith Rajagopalan emphasized the company’s conviction in the Revita platform for post-GLP-1 weight m ...

Spectral Medical is a clinical-stage medical device company developing therapies for critical care, with a focus on septic ...

Recognized healthcare analytics leader to scale delivery of the Company's health insurance denials remediation platformNEW YORK, March 24, 2026 ...

Elevation Marketing reports the healthcare software market, valued at $84 billion, grows rapidly while hospitals make ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at health insurance providers stocks, ...

Q4 2025 earnings call recap: 71% revenue growth, AI-driven benefits platform expansion, and 2026 guidance of $45–$50M—read now.

Wave Life Sciences (WVE) plunged nearly 50% on Thursday to reach a 52-week low as analysts argued that updated results from an early-stage trial for its weight-loss drug WVE-007 missed their ...

Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating and setting a ...

EO14168 has been overwhelmingly responsible for driving changes to federal forms and survey data,” says Melanie Klein, an ...